Progyluton

Selected form

Method of action: Antiplasmic, Endocrine Therapy, Sex Hormones And Modulators Of The Genital System

Treatment option: Hormone Replacement Therapy, Osteoporosis, Prevention Of Osteoporosis

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Progyluton

Property	Description
Active Ingredient(s)	Estradiol, Norgestrel
Form	Coated tablets
Pharmacological Class	Sex hormones and modulators of the genital system
Common Therapeutic Type	Sequential Combined Hormone Replacement Therapy (HRT)
Origin	Synthetic

Defining Progyluton: Classification and Therapeutic Type

Progyluton is a Sequential Combined Hormonal Preparation, categorized under the high-level pharmacological class of Sex hormones and modulators of the genital system. It is an oral, prescription-only combination product utilized as a specific type of Hormone Replacement Therapy (HRT). This classification establishes the medicine's role in addressing hormone deficiency by providing systemic supplementation. The pharmacological action is defined as hormonal replacement therapy, as the drug is a standard therapeutic approach for managing conditions linked to inadequate sex hormone levels.

Composition of Progyluton: Estradiol and Norgestrel

The active constituents in Progyluton are two synthetic sex hormones: Estradiol and Norgestrel. Estradiol serves as the replacement estrogen, which is chemically identical to the primary human estrogen, while Norgestrel functions as the progestogen component. The combination of estradiol and norgestrel is utilized for its profile within HRT regimens. This medicine is an oral formulation, presented as coated tablets intended for systemic administration. The inclusion of these two distinct, synthetic hormone classes defines its status as a combination product for comprehensive therapy.

Purpose of the Sequential Hormonal Regimen

The core purpose of Progyluton's design is to alleviate systemic discomforts by restoring a hormonal balance that follows a predictable, cyclical pattern. A typical neutral use scenario involves managing symptoms in postmenopausal women who retain their uterus. In these patients, the inclusion of the progestogen, Norgestrel, provides a vital protective mechanism. Progestogens are included in combined HRT to counter the effects of unopposed estrogen on the endometrium. This protective counter-balance is an essential safety feature, meaning the progestogen component works to prevent the uterine lining from over-developing, a clinical necessity when administering estrogen.

Regulatory References

What side effects are possible with Progyluton?

Possible Side Effects and Safety Information

Progyluton is a combined hormone preparation, and its safety profile is defined by the known risks associated with Hormone Replacement Therapy (HRT). This section summarizes potential adverse reactions and official safety limitations without providing clinical advice.

Serious and Clinically Significant Risks

Official regulatory documents identify several serious adverse reactions, which may necessitate immediate discontinuation:

Thromboembolic Events: Increased risk of venous and arterial blood clots, including deep vein thrombosis, pulmonary embolism, stroke, and myocardial infarction. This risk increases with age and duration of use.
Malignancies: The risk of developing estrogen-dependent tumors is increased, specifically breast cancer (risk rises with prolonged use, typically >5 years), endometrial cancer, and ovarian cancer. Rare cases of benign or malignant liver tumors have also been documented, which can lead to life-threatening intra-abdominal hemorrhage.
Other: Sudden impairment of vision or hearing, sudden severe headaches (migraine onset), or significant increase in blood pressure.

Common Adverse Reactions

The most frequently reported side effects include bleeding irregularities (spotting, breakthrough bleeding), breast tenderness/pain, headaches, fluid retention (bloating), and gastrointestinal symptoms like nausea or vomiting. These events are generally classified as common.

Safety Limitations and Contraindications

Progyluton is contraindicated in individuals with a history of or current thromboembolic disorders, active or suspected breast or other sex-hormone-dependent cancers, untreated endometrial hyperplasia, severe liver disease, or known hypersensitivity to the components. Treatment should be closely monitored in individuals with risk factors for cardiovascular disease, hypertension, or certain pre-existing conditions like diabetes or severe hypertriglyceridemia. The lowest effective dose should be used for the shortest possible duration to manage symptoms and mitigate risks.

Overdose and Emergency Response

The regulatory information concerning a Progyluton (Estradiol/Norgestrel) overdose focuses on the expected clinical response to hormone excess and the official actions required by prescribing information.

Documented Overdose Manifestations

Acute overdose presentations are primarily associated with symptoms of gastrointestinal and hormonal effects. Officially documented manifestations include nausea and vomiting. Other clinical signs recorded in regulatory documents are giddiness (dizziness), tiredness, and headache. A specific hormonal effect noted is vaginal bleeding, characterized as withdrawal bleeding, which can occur in women and girls.

Emergency Response and Management

Official prescribing information establishes that an acute overdose is not typically documented as life-threatening. However, the regulatory mandate is explicit: in case of any overdose, it is necessary to seek immediate medical attention or contact a Poison Control Center right away. This urgent action is required regardless of initial symptom severity to ensure proper assessment. Treatment of a Progyluton overdose is strictly symptomatic and supportive, as regulatory agencies confirm that no specific antidote is known to exist for the effects of excess estrogen and progestogen. Management therefore focuses solely on addressing the presenting symptoms and monitoring the patient's condition.

Therapeutic Uses of Progyluton

What Progyluton Treats: Main Uses and Benefits

Progyluton is a sequential combined preparation relevant in conditions characterized by periods of heightened symptoms associated with hormone deficiency in women. The therapeutic relevance for this medication generally spans the management of menopausal symptoms, menstrual cycle regulation, and long-term supportive health maintenance.

It is commonly used in clinical settings that involve acute or unstable symptom patterns, and may assist with symptomatic relief from pronounced systemic and neurological discomforts that characterize the menopausal transition. It is used for managing symptom clusters that may become intense or disruptive, such as hot flashes, night sweats, and related psychological disturbances. The key therapeutic indications include treating signs of estrogen deficiency, managing irregular menstrual cycles, and providing supportive care for postmenopausal bone thinning.

“The sequential approach assists with maintaining functional stability and managing cyclical distress in women experiencing hormone deficits.”

This preparation is relevant for easing symptoms related to inflammatory or irritative states, such as vaginal dryness and irritation, and is considered relevant for easing the impact of long-term hormone deficiency. It contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

Quick Fact: Relief for Vasomotor Symptoms
This medication is applied in addressing frequent hot flashes and night sweats, which are symptoms related to systemic imbalance that interfere with daily functioning.

Eligibility and Restrictions for Use

Who Can and Cannot Use Progyluton?

The population eligibility for Progyluton is strictly defined by regulatory authorities and is based on pre-existing medical conditions, physiological state, and age. The medicine is intended for adult women with an intact uterus who require sequential combined Hormone Replacement Therapy (HRT) for conditions like menopausal symptoms or menstrual rhythm disorders.

Progyluton is absolutely contraindicated (must not be used) in patients with a history of or active venous or arterial thromboembolic events (e.g., deep vein thrombosis, stroke, myocardial infarction) or known risk factors for these conditions. Use is also prohibited in patients with existing or suspected breast cancer or any other sex hormone-dependent malignancy, severe liver disease, untreated endometrial hyperplasia, or undiagnosed vaginal bleeding.

Population Restrictions

Population Group	Regulatory Status
Pregnancy and Lactation	Contraindicated
Children and Adolescents	Not indicated for use (Safety data unavailable)
Severe Hepatic Impairment	Contraindicated
Renal Impairment	Not investigated (No dosage recommendations)

Patients with conditions such as hypertension, diabetes, leiomyoma (fibroids), or a history of migraine must be closely monitored during treatment, as required by official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for this combined hormonal product is strictly defined by pharmacokinetic effects that alter the systemic exposure of the active components, Estradiol and Norgestrel. This information is derived from authoritative government regulatory documents, detailing several key interaction patterns and restrictions.

Substances That May Reduce Exposure

Co-administration with enzyme-inducing substances is documented to accelerate the clearance of the hormones via hepatic enzymes, potentially leading to reduced systemic exposure. Interacting medicines in this category include certain anti-epileptics such as Phenytoin and Carbamazepine, and anti-tuberculosis agents like Rifampicin. The herbal product St. John's Wort is also formally classified as an enzyme inducer that may diminish effectiveness.

Interactions Increasing Exposure and Contraindications

Potent inhibitors of the CYP3A4 enzyme (e.g., Ketoconazole, Erythromycin) may decrease hormone clearance, resulting in increased plasma concentrations. The medicine is formally contraindicated with the Hepatitis C combination regimen containing Ombitasvir, Paritaprevir, and Ritonavir (with or without Dasabuvir), due to the documented risk of liver enzyme elevations. Furthermore, the estrogen component affects circulating binding globulins, which is documented to necessitate a dose increase for co-administered replacement thyroid hormones such as Levothyroxine. The medicine is also contraindicated in patients with severe hepatic impairment due to compromised clearance.

Mechanism of Action

Progyluton's mechanism of action involves the sequential administration of two steroid components: estradiol valerate and norgestrel. Estradiol valerate, a precursor, is rapidly hydrolyzed in vivo to 17 beta-estradiol, the primary active estrogen. This estrogen component acts as an agonist by binding to and activating intracellular estrogen receptors ( ERalpha and ERbeta) primarily within target cells of the hypothalamus, pituitary, and reproductive tissues.

This binding triggers the translocation of the receptor-ligand complex into the nucleus, where it modulates the transcription of specific genes, influencing protein synthesis and cellular function.

The norgestrel component, a synthetic progestin, binds with high affinity to intracellular progesterone receptors ( PR). This interaction alters gene expression in the endometrium. The combination of estrogen and progestin exerts a coordinated effect on the hypothalamic-pituitary-gonadal (HPG) axis. The administered hormones induce a negative feedback loop on the hypothalamus and pituitary gland, specifically inhibiting the pulsatile release of gonadotropin-releasing hormone (GnRH) and the subsequent secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the anterior pituitary. This suppression of gonadotropins is the final systemic consequence of its pharmacodynamic mechanism.

Dosage and Administration Information

Progyluton is a cyclical hormonal preparation administered orally as coated tablets. The treatment follows a structured 28-day cycle consisting of 21 days of active tablets followed by a 7-day tablet-free interval. The fundamental principle guiding this therapy is the use of the lowest effective dose for the shortest possible duration consistent with the clinical objective.

Administration Scope

The regimen requires taking one tablet daily from the calendar pack. The tablets are sequentially formulated in two phases: the first 11 tablets are white, containing 2 mg estradiol valerate, followed by 10 light brown tablets, which combine 2 mg estradiol valerate with 0.5 mg norgestrel. To ensure consistent hormone levels, the daily tablet should preferably be taken at the same time every day, and must be swallowed whole with liquid.

Labeled Scheduling and Procedural Rules

Treatment initiation depends on the patient's menstrual status. Women who are still having regular periods typically start the first tablet on the fifth day of their cycle. If a patient is amenorrhoeic or has irregular bleeding, the first tablet may be started at any time after ruling out pregnancy. A crucial procedural rule is that the tablets must be taken sequentially according to the chronological order on the pack, transitioning from the estrogen-only to the combined tablets.

The cycle repeats after the 7-day break, with a new pack always starting on the same day of the week. If a tablet is forgotten at the usual time, it should be taken as soon as possible. However, if more than 24 hours have elapsed, the missed tablet should be skipped to continue the regimen on schedule, although skipping a dose may lead to irregular bleeding. For older adults (65 years and older), no dose adjustment is generally necessary. The medicine is not indicated for use in children or adolescents under 18 years of age.

Recent Clinical Evidence

Research evidence / Overview of Studies for Progyluton

Research related to the use of combined hormone therapy, of which Progyluton is a part, has been conducted to explore outcomes associated with hormone deficiency. The evidence is drawn from multiple sources, including Randomized Controlled Trials (RCTs) and long-term observational studies of the overall HRT class, alongside specific pharmacological studies. This overview summarizes the structure of the research evidence.

Evidence for Managing Vasomotor Symptoms

Clinical evaluation involves short-term RCTs and analyses of larger Prospective Epidemiological Studies that examine the broader HRT class. Studies report how symptoms evolved in peri- and postmenopausal women, with findings describing patterns where the frequency and severity of hot flashes and night sweats were measured in treated participants. Long-term effects are not fully established using data specific to this particular estradiol/norgestrel formulation, as high-level chronic data is generally derived from the overall HRT class.

Evidence for Regulating the Menstrual Cycle

The research for this indication was evaluated in conditions associated with irregular bleeding. Studies monitored outcomes related to systemic or functional imbalance, specifically concerning the expected cyclical pattern in women who possess an intact uterus. Findings indicate that the sequential administration of the progestogen component, norgestrel, was observed in studies where participants reported a cyclical pattern of uterine bleeding. Comparative evidence is lacking regarding norgestrel versus other progestogens for achieving cycle stability.

Evidence for Postmenopausal Bone Thinning

Progyluton was evaluated in studies related to postmenopausal bone thinning. Research examined outcomes related to systemic or functional imbalance, specifically focusing on Bone Mineral Density (BMD) and the incidence of fractures. Data show patterns related to a measured change in BMD over periods of five years or more. However, the evidence supporting this specific combination is often drawn from the broader findings for the HRT class as a whole, and long-term effects are not fully established for all subgroups. Comparative evidence between Progyluton and other specific HRT products is limited.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Progyluton (FAQ)

Q: What is Progyluton used for?

A: Progyluton contains two active components: Estradiol valerate and Norgestrel. It is indicated for use in hormone replacement therapy (HRT) to manage symptoms associated with menopause and to treat primary or secondary amenorrhea (absence of menstrual periods) in individuals who are not pregnant.

Q: How does Progyluton work?

A: Progyluton is a combination hormonal preparation. The estradiol valerate component acts as an estrogen, replacing the body's natural estrogen. The norgestrel component is a progestogen added to protect the lining of the uterus (endometrium) in individuals who still have a uterus, reducing the risk of endometrial hyperplasia.

Q: When should I take Progyluton?

A: The use of Progyluton should be discussed with a healthcare provider. The prescribing information outlines a sequential regimen where the pink tablets containing only estrogen are taken for a period, followed by the white tablets containing both estrogen and progestogen. This regimen mimics a natural cycle.

Q: What side effects are commonly associated with Progyluton?

A: Clinical trials and post-marketing surveillance have observed common side effects. These may include headache, nausea, abdominal pain, breast tenderness, and mood changes. A complete list of reported effects is available in the official prescribing information.

How should Progyluton be stored and disposed of?

How to Store and Dispose of Progyluton?

Official Storage Requirements

Progyluton coated tablets must be stored according to specific constraints to maintain their stability. While some regulatory documents require storage below 25 C, others indicate that no special temperature conditions are mandatory. A universal requirement is that the medication must be kept in its original outer carton and blister packaging to ensure protection from light and moisture. Crucially, the product must be stored out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Unused or expired Progyluton must not be thrown away with household waste or disposed of via wastewater (drains or toilets). Instead, the official instructions require that the medication be returned to a pharmacist or be disposed of through an authorized local pharmaceutical waste collection program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.